InMed Pharmaceuticals Inc. (INM) News
Filter INM News Items
INM News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
INM News Highlights
- INM's 30 day story count now stands at 2.
- Over the past 20 days, the trend for INM's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- RARE and AMD are the most mentioned tickers in articles about INM.
Latest INM News From Around the Web
Below are the latest news stories about INMED PHARMACEUTICALS INC that investors may wish to consider to help them evaluate INM as an investment opportunity.
InMed Announces Results of 2023 Annual General MeetingVancouver, British Columbia--(Newsfile Corp. - December 19, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today confirmed that, at its annual general meeting of shareholders held on December 19, 2023 (the "Meeting"), all of the matters put forward before shareholders for consideration and approval as set out in InMed's notice of meeting and managemen |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayChecking out the biggest pre-market stock movers for Tuesday is the perfect way to get ready for another busy day of trading! |
InMed Expands its Pharmaceutical Pipeline with INM-089 targeting the treatment of Age-Related Macular DegenerationINM-089 improves retinal function in in vivo preclinical AMD disease modelEstablishes cannabinol (CBN) analog candidate in a new disease targetVancouver, British Columbia--(Newsfile Corp. - November 29, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announces the launch of INM-089, a cannabinol ("CBN") analog, to investigate i |
InMed Reports First Quarter Fiscal 2024 Financial Results and Provides Business UpdateVancouver, British Columbia--(Newsfile Corp. - November 14, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today reports financial results for the first quarter of the fiscal year 2024 which ended September 30, 2023.The Company's full financial statements and related MD&A for the first quarter ended September 30, 2023, are available |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayPre-market stock movers are a hot topic on Wednesday and we're starting the morning with a breakdown of the biggest ones. |
InMed Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023Vancouver, British Columbia--(Newsfile Corp. - November 2, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announced that an abstract describing the Phase 2 clinical study of investigational drug INM-755 cannabinol ("CBN") cream for the treatment of symptoms in patients with epidermolysis bullosa ("EB"), a rare genetic skin dis |
InMed Pharmaceuticals Announces the Closing of $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market Under Nasdaq RulesVancouver, British Columbia--(Newsfile Corp. - October 26, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announced that it has closed its previously announced offering for the issuance and sale of 3,012,049 pre-funded warrants and preferred investment options to purchase up to an aggregate of 3,012,049 common shares, at a pur |
EVGO Stock Slips as TD Cowen Downgrades EVgoEVgo stock is taking a beating on Wednesday as investors in the EV charging company deal with a downgrade and price cut. |
Why Is BioXcel Therapeutics (BTAI) Stock Up 42% Today?BioXcel Therapeutics stock is rising on Wednesday as investors in BTAI stock react to results from an audit on a clinical trial. |
Why Is InMed Pharmaceuticals (INM) Stock Down 25% Today?InMed Pharmaceuticals stock is falling on Wednesday after shares of INM underwent a massive rally on Tuesday alongside study results. |